Effectiveness and Tolerability of Tomoxetine in Adults With Attention Deficit Hyperactivity Disorder
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
Spencer, ThomasBiederman, Joseph
Wilens, Timothy
Prince, Jeffry
Hatch, Mary
Jones, Janice
Harding, Margaret
Faraone, Stephen V.
Seidman, Larry
Keyword
Psychiatry and Mental healthJournal title
American Journal of PsychiatryDate Published
1998-05Publication Volume
155Publication Issue
5Publication Begin page
693Publication End page
695
Metadata
Show full item recordAbstract
Objective: The authors assessed the experimental noradrenergic compound tomoxetine as an alternative treatment for adult attention deficit hyperactivity disorder (ADHD). Method: They conducted a double-blind, placebo-controlled, crossover study of tomoxetine in 22 adults with well-characterized ADHD. Results: Treatment with tomoxetine at an average oral dose of 76 mg/day was well tolerated. Drug-specific improvement in ADHD symptoms was highly significant overall and sufficiently robust to be detectable in a parallel-groups comparison restricted to the first 3 weeks of the protocol. Eleven of 21 patients showed improvement after receiving tomoxetine, compared with only two of 21 patients who improved after receiving placebo. Significant tomoxetine-associated improvement was noted on neuropsychological measures of inhibitory capacity from Stroop tests. Conclusions: This preliminary study showed that tomoxetine was effective in treating adult ADHD and was well tolerated. These promising results provide support for further studies of tomoxetine over an extended period of treatment.DOI
10.1176/ajp.155.5.693ae974a485f413a2113503eed53cd6c53
10.1176/ajp.155.5.693
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International